【藥品庫存】 本藥品為臨時採購藥品，經院長核可後，限定特定科別、病人使用。

Breast cancer, Ovarian cancer, Pancreatic cancer, Prostate cancer

laparib is a potent oral PARP inhibitor which induces synthetic lethality in BRCA1/2 deficient tumor cells through the formation of double-stranded DNA breaks which cannot be accurately repaired, which leads to disruption of cellular homeostasis and cell death.

Hypersensitivity to olaparib or any component of the formulation.

In utero exposure to olaparib may cause fetal harm.

Lactating females should not breastfeed during treatment and for 1 month after the last olaparib dose.

300 mg twice daily until disease progression or unacceptable toxicity.

CrCl 31 to 50 mL/minute: Reduce dose to 200 mg twice daily.
CrCl ?30 mL/minute, End-stage renal disease: Has not been studied.

No dosage adjustment necessary.

Store at room temperature below 30 degree C.